Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement
Supplemental
Segments

Unit Economics
Common Size IS
Op Efficiency
Credit Analysis

LIGAND PHARMACEUTICALS INC (LGND)

Income Statement Business | Product

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsJun-30-23Mar-31-23Dec-31-22Sep-30-22Jun-30-22Mar-31-22Dec-31-21Sep-30-21
   10-Q10-Q8-K10-Q10-Q10-Q10-K10-Q
Total revenues   [+]26.444.050.466.150.136.572.564.8
            Revenue growth  -47.4%20.4%-30.5%1.9%-40.8%-33.8%3.5%54.9%
Cost of goods sold  8.58.539.411.88.68.611.811.8
Gross profit  17.835.411.054.341.627.960.753.0
            Gross margin  67.6%80.6%21.9%82.1%82.9%76.5%83.8%81.8%
Selling, general and administrative   [+]11.310.931.117.412.111.917.712.7
Research and development  6.96.7 22.08.59.218.216.9
Equity in earnings          
EBITDA   [+]7.523.7 14.121.915.825.928.4
            EBITDA margin  28.5%53.9%-39.9%21.4%43.7%43.2%35.7%43.8%
Depreciation and amortization  9.59.5 13.513.313.713.212.7
EBIT   [+]-2.014.2-20.10.68.72.112.715.7
            EBIT margin  -7.5%32.3%-39.9%1.0%17.3%5.8%17.6%24.2%
Interest expense, net   [+]-2.0-1.2-0.8-0.30.10.74.34.3
Other income (expense), net   [+]3.140.143.50.00.1-10.6-15.53.8
Pre-tax income  3.255.524.10.98.7-9.1-7.015.3
Income taxes  0.911.938.70.5-3.93.8-1.61.5
            Tax rate  27.8%21.5%160.2%52.9%  22.9%10.1%
Earnings from continuing ops  2.343.6-14.50.412.6-12.9-5.413.7
Earnings from discontinued ops    -3.0     
Net income  2.341.9-17.50.4-0.9-15.4-5.413.7
            Net margin  8.7%95.4%-34.7%0.6%-1.8%-42.1%-7.5%21.2%
   
Basic EPS   [+]$0.13$2.56($0.86)$0.02$0.75($0.77)($0.33)$0.82
Diluted EPS   [+]$0.13$2.43($0.86)$0.02$0.74($0.77)($0.31)$0.80
   
Shares outstanding (basic)   [+]17.317.116.816.916.916.816.616.7
Shares outstanding (diluted)   [+]17.718.016.817.117.116.817.217.1
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy